FDA approves long-acting flea treatment for dogs, marking veterinary breakthrough
The U.S. Food and Drug Administration has given the green light to Bravecto Quantum, the first-ever flea and tick preventative that can protect dogs for up to 12 months with a single injection. The treatment is approved for dogs and puppies 6 months and older.
The new shot is an alternative to treatments that usually need to be given every month or every few months.
"Fluralaner, the active ingredient in Bravecto Quantum, can be an important part of parasite control depending on where pet owners live in the country," said Dr. Tina Wismer, senior director of toxicology at ASPCA Poison Control, in an email to ABC News. "A long-term flea and tick preventative can be a useful option for dog owners who live in areas where year-round protection is necessary, or for those who might not be able or remember to administer treatment on a monthly or quarterly basis."
MORE: Male infertility: 5 lifestyle factors that could be hurting your fertility
The injectable treatment must be administered by a licensed veterinarian, who will determine whether an 8- or 12-month protection period is appropriate based on local tick species. Veterinarians will also monitor for potential side effects.
While the drug belongs to a commonly used and safe class of medications called isoxazolines, some dogs may experience neurologic side effects, including muscle tremors and seizures.
Julie Cappiello, with Voters For Animal Rights, an advocacy organization, said she welcomes the new treatment but emphasized caution.
"As someone who spends a great deal of time outdoors with my dog, I see the convenience of a long-lasting, 12-month flea and tick preventative like Bravecto Quantum," she said in a statement. "However, it's important to recognize that no single treatment is right for every dog, and all medications come with potential risks."
The new treatment is manufactured by Intervet, Inc., based in Rahway, New Jersey.
Pet owners interested in the new treatment option should consult their veterinarians to determine if it's appropriate for their dogs, particularly those with a history of neurological issues.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Retiree health care costs are climbing: What advisors need to know
Health care costs for retirees just keep rising. A 65-year-old retiring in 2025 can expect to spend $172,500 on health care costs and medical expenses throughout retirement, according to a new survey from Fidelity. Financial advisors say ignoring that number can be a costly decision for retirees. Since Fidelity began tracking retiree health care costs in 2002 — when the estimated expense for a 65-year-old was just $80,000 — projected costs have steadily climbed, far outpacing inflation. In the past year alone, Fidelity reported a 4% increase in total expected health care spending for retirees. READ MORE: A health care planning checklist for financial advisorsLong-term care costs can derail retirement plans. Here's how to manage themWhy protecting wealth starts with planning for health careSocial Security is changing — here's how advisors are preparing The estimate includes out-of-pocket prescription drug costs, Medicare premiums and other medical expenses, such as co-payments and deductibles. Researchers did not include potential costs from other health care-related expenses, including over-the-counter medications, most dental services and long-term care. Many retirees have found themselves ill-equipped to handle those costs, according to Shams Talib, head of Fidelity Workplace Consulting. "Year after year, so many Americans underestimate how much they'll need to save to cover health care costs in retirement," Talib said. "We recognize the impact health care costs can have on retirement savings. With the right tools and guidance, pre-retirees and retirees alike can take greater control of their financial futures by beginning the planning process as soon as possible." Clearing up Medicare misconceptions Financial advisors say one of the biggest impediments to planning for health care costs in retirement is a misconception about the role of Medicare. Namely, that it will cover more medical expenses than it does. "When I have these conversations with clients, especially those who are unprepared, the first step is just helping them slow down," said Melissa Cox, owner of Future-Focused Wealth in Dallas, Texas. "There's often a mix of embarrassment and fear. Many say, 'I didn't know this was something I needed to think about.' We walk through Medicare together, clarify what's covered and what isn't, and start looking at how their current financial picture can support a more realistic health care forecast." That picture can start to look very different depending on how short they are of covering estimated medical expenses. "Sometimes we have to pivot, adjust spending, reframe goals or revisit timelines, but that's okay," Cox said. "What matters most is giving people a sense of control over something that felt out of reach." Encourage clients to plan early Preparing for health care costs in retirement can be a relatively straightforward process as long as clients start early, advisors say. Near-retirees have several cost-effective options to help cover expenses, including Medigap, long-term care insurance and life insurance with care-related riders. But for older retirees seeking coverage later, the process becomes more complex and often more expensive. According to Andrew Crowell, vice chairman of wealth management for D.A. Davidson in New York City, waiting too long to sign up for certain plans can make them difficult to obtain at all. "I've had some clients recently, in good health but in their 70s, who were looking for a little extra coverage. … Both of them [were] denied coverage because they couldn't pass a cognition test," Crowell said. "I have perfectly lucid conversations with them all the time, but the test that they were given was an individual over the phone reading a long list of words, and then they were asked to repeat back as many of the words they remembered hearing in the short space, and they froze up. They stammered through a few of them, and the insurance just denied them on that, and they have no aches, no pains, no typical aging stuff." If those same clients had tried to sign up for policies in their 50s or 60s, the situation would have looked very different, Crowell said. "If we had done that in their 60s or in their 50s — young, healthy — they would have qualified for a great preferred rate premium, and it wouldn't be an issue," he said. "Now they can try to reapply, but you know they're going to have the jitters from the minute they reapply, and they're probably going to freeze up again just because of that." Crowell, who has been working in the industry for over 30 years, said insurance companies are becoming more cautious when assessing people due to increasing longevity. When it's too late to start early Starting early is one of the most effective strategies in financial planning — and health care planning is no exception. But even for clients who come to an advisor later in life, there are still viable options to manage rising medical costs. "When I work with clients who are unprepared for these costs, the conversation often shifts to what they value most in their retirement plan," said Beau Kemp, a financial advisor at SwitchPoint Financial Planning in Lehi, Utah. "If the plan goes from looking good to looking constrained with the increased health care costs, we have to make some adjustments." Exactly what those adjustments look like depends on the client's lifestyle preferences, Kemp said. Clients set on maintaining their current lifestyle may need to delay retirement as they build up their savings. Others who are more concerned with retiring at a specific age may have to scale back their spending to make room for medical costs. "I rarely decrease the projected medical expenses in a plan because these costs are largely out of our control," Kemp said. "The focus needs to be on what we can control and if a client is comfortable with those adjustments. The goal is to create a plan that provides both financial security and peace of mind."
Boston Globe
6 minutes ago
- Boston Globe
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Marlborough-based Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. Advertisement In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. Advertisement As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading.
15 minutes ago
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
WASHINGTON -- U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. The Food and Drug Administration issued two alerts Wednesday about electrical problems tied to the company's heart-zapping defibrillator systems and a separate issue with a heart implant used to reduce stroke risk. The agency said the company's Endotak Reliance defibrillator wires can become calcified, leading to failures in delivering life-saving shocks to the heart, according to the FDA. Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
